Stockreport

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumo [Read more]